Roflumilast Cream 0.05%

Drug identity checked against registry records

Also recorded as ARQ-151

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)NCT04845620ARQTPhase 3Completed2023-06-01Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.